Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone and buprenorphine for opioid use disorder induction
NCT02537574Phase 3Completed
- Sponsor
- Alkermes
- Start
- Aug 2015
- Primary completion
- Oct 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of naltrexone, buprenorphine in opioid use disorder (OUD), sponsored by Alkermes. Started Aug 2015; status: completed.
02
Drugs
naltrexonebuprenorphine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT02537574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02537574.